There have been a number of studies exploring the use of low-dose naltrexone (LDN) in cancer patients. Here are a few examples:
- In a small pilot study published in 2013, researchers evaluated the safety and efficacy of LDN in patients with pancreatic cancer. They found that LDN was well-tolerated and appeared to have anti-tumor effects, with a median progression-free survival of 4.4 months and a median overall survival of 12.7 months.
- A 2014 study examined the effects of LDN in combination with standard chemotherapy in patients with advanced ovarian cancer. The researchers found that LDN appeared to enhance the efficacy of chemotherapy and improve quality of life, with fewer side effects than chemotherapy alone.
- A 2018 review of the literature on LDN and cancer suggested that LDN may have broad anti-cancer effects by modulating the immune system, reducing inflammation, and promoting apoptosis (programmed cell death) in cancer cells. The authors concluded that further research is needed to better understand the potential of LDN as a cancer treatment.
- A 2019 study explored the effects of LDN in patients with metastatic breast cancer. The researchers found that LDN was well-tolerated and appeared to have anti-tumor effects, with a median progression-free survival of 2.2 months and a median overall survival of 12.6 months.
It’s worth noting that while there is some evidence to suggest that LDN may be a useful adjunct therapy for some cancer patients, more research is needed to fully understand its potential benefits and risks. Patients considering LDN should discuss their options with a qualified healthcare provider.